Regen BioPharmaRGBP +7.14% Debt-to-EBITDA is 0.23 as of Mar. 2026. The stock has 7 warning signs investors should review. Among 291 Biotechnology companies, Regen BioPharma ranks worse than 343642.27% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Regen BioPharma's Debt-to-EBITDA or its related term are showing as below:
RGBP'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.33 Med: -0.29 Max: 0.62
Current: -1.9
During the past 13 years, the highest Debt-to-EBITDA Ratio of Regen BioPharma was 0.62. The lowest was -2.33. And the median was -0.29.
RGBP's Debt-to-EBITDA is ranked worse than 100% of 291
companies
in the Biotechnology industry
Industry Median: 1.14
vs RGBP: -1.90
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Regen BioPharma Debt-to-EBITDA Related Terms
Regen BioPharma Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Regen BioPharma's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RGBP vs SIGY, ENDV, CNBX: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Regen BioPharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regen BioPharma Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regen BioPharma's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Regen BioPharma's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Regen BioPharma (RGBP) has a Debt-to-EBITDA of 0.23 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Regen BioPharma. According to the industry distribution chart, Regen BioPharma ranks #999999 out of 291 companies in the Biotechnology industry.
Is Regen BioPharma's Debt-to-EBITDA too high?
Regen BioPharma's current Debt-to-EBITDA is 0.23. The Biotechnology industry median Debt-to-EBITDA is 1.14. Regen BioPharma's value of 0.23 is 79.8% below this industry median. Based on the distribution chart, Regen BioPharma ranks #999999 out of 291 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Regen BioPharma's Debt-to-EBITDA compare to SIGY and ENDV?
According to the Biotechnology industry distribution chart, Regen BioPharma ranks #999999 out of 291 companies for Debt-to-EBITDA. This places Regen BioPharma in the lower half of its industry. The industry median Debt-to-EBITDA is 1.14. Regen BioPharma's value of 0.23 is 79.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.14, based on 291 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Regen BioPharma's current Debt-to-EBITDA of 0.23 is 79.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Regen BioPharma. For the Biotechnology industry, the median Debt-to-EBITDA is 1.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regen BioPharma's current Debt-to-EBITDA is 0.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regen BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Regen BioPharma (RGBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.02, compared to a current price of $0.00 — trading 99.3% below its estimated fair value. The current Debt-to-EBITDA is 0.23 and 79.8% below the Biotechnology industry median of 1.14. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Regen BioPharma (RGBP), the current Debt-to-EBITDA is 0.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGBP has been successfully added to your 